The future of market research

Asthma and COPD Drugs Market Trends, Growth and Insights by Disease (COPD and Asthma), Product (Long-Term Asthma Control Drugs, Rapid-Relief Drugs), Route of Administration (Oral, Inhalation), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online pharmacies) and region (Americas, Europe, Asia-Pacific, Middle East and Africa), competitive market size, share and forecast to 2030.

New York, USA, December 14, 2022 (GLOBE NEWSWIRE) — Asthma and COPD Drug Market Overview

According to a comprehensive research report by Market Research Future (MRFR), “Asthma and COPD drug market Information by Disease, Product, Administration and Distribution Channel and Region – Forecast to 2030”, the market is projected to reach USD 34,374.23 million by 2030 at a CAGR of 4.20% during the forecast period 2022-2030.

Market Brief

A respiratory disorder known as asthma is characterized by episodes of bronchial spasm that make breathing difficult. It is often associated with allergic reactions or other types of hypersensitivity. A collection of respiratory diseases known as COPD causes narrowing of the airways and uncomfortable or difficult breathing.

Asthma and COPD can be prevented and controlled using corticosteroids, short-acting beta agonists, and anticholinergic medications. A patient experiences breathing problems during an acute asthmatic episode because the bronchi suddenly narrow, usually as a result of allergens. Bronchodilators provide immediate relief during asthma attacks and can even save a patient’s life.

In order to develop drugs that will give patients with asthma and chronic obstructive pulmonary disease (COPD) a higher quality of life, researchers have targeted different sites in the airways and lungs (COPD). They have created a brand new drug that will clear mucus from the airways, making it easier for patients to breathe than before. In addition, the businesses have received regulatory approvals. Drug development for COPD and asthma will begin in the coming years.

Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/8749

The scope of the report.

Report a feature

Details

Market size in 2030

USD 34374.23 million

CAGR:

4.20%

Base year

2021

Forecast period

2022-2030

Historical data

2020

Prediction units

Value (million USD)

Report coverage

Revenue Forecast, Competitive Landscape, Growth Factors and Trends

Sections covered

By disease, product, route of administration and distribution channel.

Geographies covered

North America, Europe, Asia-Pacific and Rest of the World (RoW)

Main market drivers

Increasing prevalence and incidence rates of asthma and COPD

Rapidly changing lifestyles and high R&D costs

Competitive Landscape of the Asthma and COPD Drug Market:

Important participants in the Asthma and COPD drugs industry include:

The market for COPD and asthma drugs is competitive and consolidated. The market is competitive and large companies are engaging in mergers and acquisitions, new product development, partnerships and collaborations, and growth programs to increase market penetration.

A generic version of Formoterol Fumarate Inhalation Solution, used to treat chronic obstructive pulmonary disease (COPD), was launched in November 2022, according to pharmaceutical giant Lupine Ltd. (COPD). To compete with Mylan Specialty’s Perforomist Inhalation Solution, 20 mcg/2 ml, Lupine announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 ml per unit dose vial.

Asthma and COPD Drug Market Dynamics.

Market drivers.

Asthma and COPD can be prevented and controlled using corticosteroids, short-acting beta agonists, and anticholinergic medications. A patient experiences breathing problems during an acute asthmatic episode because the bronchi suddenly narrow, usually as a result of allergens. Bronchodilators provide immediate relief during asthma attacks and can even save a patient’s life.

Obtaining regulatory agency approval is critical as new pharmaceutical products enter the market. The first generic version of Symbicort from AstraZeneca has been approved by the US Food and Drug Administration (FDA). Breyna (budesonide and formoterol fumarate dehydrate), developed by Viatris and Kindeva Drug Delivery, has received FDA approval. It is a medicine that is inhaled and can be used to treat COPD and asthma. Patients over six years of age with these diseases can use this medicine. People with severe asthma should not use this inhaler, according to the FDA.

The prevalence and incidence of asthma have increased significantly, increasing the number of patients and increasing the demand for these drugs. Asthma is an important non-communicable disease (NCD) that affects both children and adults, according to the World Health Organization (WHO) 2021. In 2019, it reportedly adversely affected 262 million people worldwide and killed 461,000 people. Key market players have business strategies that include significant investments in asthma drug research as well as strategic alliances such as mergers and acquisitions.

In addition, the global market for drugs to treat COPD and asthma is expanding due to an aging population. According to the Global Aging Project 2020, in 2020 there will be approximately 727 million people in the world who are 65 years of age or older. By 2050, the world’s elderly population is projected to reach 1.5 billion. The percentage of people aged 65 and over worldwide increased from 9.3% in 2020 to 16% in 2050. As a result, this factor contributes to the growth of the global market. asthma and COPD medications.

Browse the in-depth market research report (135 pages). Asthma and COPD medications: https://www.marketresearchfuture.com/reports/asthma-copd-drugs-market-8749

Market restrictions.

Factors including stringent government requirements for product approval and pharmacological side effects are expected to restrain market growth during the forecast period.

Analysis of COVID-19

A study by José Luis Izquierdo et al published in the European Respiratory Journal in March 2021 found that asthmatic patients with COVID-19 had a lower prevalence of allergy-related diseases such as rhinitis and eczema. These comorbidities were seen in a high percentage of COVID-19 patients who required hospital admission. In addition, compared with patients who were not hospitalized due to COVID-19, the use of inhaled corticosteroids (ICS) was reduced in patients requiring hospitalization (48.3% vs. 61.5%). Even when patients receiving biologics had more comorbidities and more severe ear, nose, and throat disease, these patients had relatively few (0.23%) COVID-19-related hospitalizations. Thus, due to comorbidity characteristics, patients with asthma and COVID-19 were older and at higher risk.

Even after adjusting for age and smoking, COPD still had an odds ratio of 2,681 for ICU hospitalization, mechanical ventilation, or death in 1,590 COVID-19 patients in China. Approximately 25% of those who died were COPD patients (compared to only 2.8% of those alive), and approximately 62.5% of severe cases had a history of COPD (compared to only 15.3% of non-severe cases). with). Simply put, the COPD and asthma drug market has been significantly impacted by the COVID-19 pandemic.

Buy now! https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=8749

Asthma and COPD Drug Market Segmentation

According to the disease

The market, depending on the disease, can be segmented into asthma as well as COPD.

By product

On the basis of product, the asthma and COPD drugs market has been segmented into short-acting asthma-relief drugs and long-acting asthma-control drugs. Long-acting beta-agonists, combination drugs, anticholinergics, inhaled corticosteroids, theophylline, and other therapies are further divided into long-term asthma control therapies. Seretide/Advair, Symbicort, Relvar/Breo Ellipta, Flutiform, Dulera, etc. are other categories for combination drugs. Anticholinergics are further divided into Spiriva and other types of drugs. Pulmicort, Flovent, Qvar, and other inhaled corticosteroids fall further into this category.

By quick relief drugs

Quick-relief medications are further divided into ipratropium bromide (Atrovent), oral and intravenous corticosteroids, short-acting beta-agonists, and others. Proair and Ventolin were developed as further subcategories of short-acting beta-agonists.

By management

On the basis of route of administration, the COPD and asthma drug market has been segmented into oral, inhalation, and others.

By distribution channel

The global asthma and COPD drugs market has been segmented into retail pharmacies, hospital pharmacies, and online pharmacies.

Share your queries @ https://www.marketresearchfuture.com/enquiry/8749

Asthma and COPD Drug Market Regional Insights

The global market for asthma and COPD drugs is projected to be dominated by the Americas. Asthma and COPD patients are becoming more common in the area, which can be attributed to this. In 2016, 8.3% of children in the United States were diagnosed with asthma, according to the American Academy of Allergy, Asthma and Immunology. Additionally, the market is expected to expand due to increasing healthcare expenditure per person and growing desire to opt for the latest treatments.

It is expected to be the second largest market for asthma and COPD drugs in Europe throughout the study. Increasing awareness of COPD and asthma in Europe is expected to drive regional market expansion.

Discover more research reports Healthcare industry by the future of market research.

Asthma inhaler marketInformation by Type (Dried Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers), Mode of Operation (Handheld Inhalers, Digital Inhalers), End User (Hospitals & Clinics, Home Care) and Region (Americas, Europe, Asia). -Pacific & Middle East & Africa) – Forecast to 2030

Chronic Obstructive Pulmonary Disease Market Research report. Information by COPD type (emphysema and chronic bronchitis), treatment type (drugs, surgery and oxygen therapy), end user (hospitals and clinics, home care settings, etc.), and region (Americas, Europe, Asia-Pacific, etc.). Middle East and Africa) – Forecast to 2027

Obstructive Pulmonary Disease Market Research Report – By Disease Type (Asthma, Bronchitis, Code), By Product Type (Inhalers, Nebulizers), Drug Class (Combination Drug, Lta, Ics, Saba, Laba), Route of Administration, End User Forecast to 2030

About the future of market research.

Market Research Future (MRFR) is a global market research company that prides itself on offering comprehensive and accurate analysis related to various markets and consumers worldwide. Market Research Future aims to provide optimal quality research and granular research to clients. Our market research by products, services, technologies, applications, end users and market players for global, regional and country level market segments enables our clients to see more, learn more and do more, helping to answer what matters most to you. questions.

Follow us: LinkedIn: |: Twitter:

CONTACT: Market Research Future (Part of Wantstats Research and Media Private Limited) 99 Hudson Street, 5Th Floor New York, NY 10013 United States of America +1 628 258 0071 (US) +44 2035 002 764 (UK) Email: sales@marketresearchfuture.com Website: https://www.marketresearchfuture.com

ودجت أحدث المقالات للصفحة الرئيسية تظهر على الصفحة الرئيسية فقط

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *